Sage Therapeutics, Inc., a biopharmaceutical company headquartered in Cambridge, Massachusetts, has announced the development and commercialization of brain health medicines. Specifically, the company's product candidates include ZULRESSO, which is a CIV injection for treating postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid that has completed Phase III clinical trials for treating PPD and major depressive disorders and is in Phase II clinical trials for treating treatment-resistant depression, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound in Phase II clinical trials for treating essential tremors while also completing Phase I clinical trials for treating Parkinson's diseases and epilepsy. Additionally, SAGE Therapeutics has SAGE-689 in Phase II clinical trials for treating acute GABA hypofunction and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, in Phase II clinical trials for treating a plethora of disorders such as depression, Alzheimer's disease, Huntington's disease, schizophrenia, neuropathic pain, and attention deficit hyperactivity disorder. SAGE Therapeutics, Inc. has also partnered with Shionogi & Co., Ltd. for the development of zuranolone in Japan, South Korea, and Taiwan while also collaborating and licensing with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc., and its name was later changed to Sage Therapeutics, Inc. in September 2011.